Pediatric multiple sclerosis Advocacy Hub | UniteRare

At a Glance

Live from database

💊

Regulatory Watchboard

10 events

Nov 2026A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

Biogen — PHASE3

TrialNOT YET RECRUITING

Feb 2026

GLATOPA: New indication approved

FDAcompleted

Dec 2025Comparison of Structured Exercise and Exergaming in Pediatric-Onset Multiple Sclerosis

Istanbul University - Cerrahpasa — NA

TrialNOT YET RECRUITING

Oct 2025A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)

Hoffmann-La Roche — PHASE2

TrialRECRUITING

Mar 2025

GLATOPA: New indication approved

FDAcompleted

Oct 2024Five Times Sit-To-Stand Test for Patients with Pediatric-Onset Multiple Sclerosis

Istanbul University - Cerrahpasa

TrialNOT YET RECRUITING

Mar 2024

GLATOPA: New indication approved

FDAcompleted

Jul 2023

GLATOPA: New indication approved

FDAcompleted

Sep 2022

GLATOPA: New indication approved

FDAcompleted

May 2022A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS)

Hoffmann-La Roche — PHASE3

TrialACTIVE NOT RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

1 program

FINANCIAL LANDSCAPE SUMMARY

Total programs

Open now

Copay cards

Copay Assistance1

Avonex

Biogen, Inc.

OpenContact for detailsApply ↗

View all support programs on disease page →

Approved Treatments

4 FDA-approved

Copaxone

(glatiramer acetate)Orphan drug

Teva Pharmaceuticals USA

12.1 Mechanism of Action The mechanism(s) by which glatiramer acetate exerts its effects in patients with MS are not fully understood. However, glatir...

Approved Dec 1996FDA label ↗

Avonex

(Interferon beta-1a)Orphan drug

Biogen, Inc.

Interferon beta [EPC]

12.1 Mechanism of Action The mechanism of action by which AVONEX exerts its effects in patients with multiple sclerosis is unknown.

Approved May 1996FDA label ↗

Novantrone

(Mitoxantrone)Orphan drugstandard

Serono, Inc.

Mechanism of Action Mitoxantrone, a DNA-reactive agent that intercalates into deoxyribonucleic acid (DNA) through hydrogen bonding, causes crosslinks ...

FDA label ↗

Remicade

(infliximab)Orphan drugstandard

Janssen Biotech, Inc.

Tumor Necrosis Factor Blocker [EPC]

12.1 Mechanism of Action Infliximab neutralizes the biological activity of TNFα by binding with high affinity to the soluble and transmembrane forms o...

FDA label ↗

View full treatment details on disease page →